ProPhase Labs, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
ProPhase Labs, Inc. (PRPH) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $227.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-19
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $17.00K, a 85.34% decline year-over-year.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $89.00K, a 20.54% decline year-over-year.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $121.00K, a 10.00% increase year-over-year.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $227.00K, a 50.33% decline from fiscal 2024.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $457.00K, a 8.55% increase from fiscal 2023.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $421.00K, a 22.74% increase from fiscal 2022.
- ProPhase Labs, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $343.00K, a 4.26% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $17.00K derived: sum of 2 quarters · filed 2026-06-01 | $106.00K derived: sum of 3 quarters · filed 2026-08-19 | $227.00K 10-K · filed 2026-06-01 |
| 2025-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $106.00K derived: sum of 2 quarters · filed 2026-08-19 | $227.00K 10-Q · filed 2025-11-19 | $346.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $89.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $210.00K 10-Q · filed 2026-08-19 | $329.00K derived: sum of 3 quarters · filed 2026-08-19 | $445.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $121.00K 10-Q/A · filed 2026-07-09 | $240.00K derived: sum of 2 quarters · filed 2026-07-09 | $356.00K derived: sum of 3 quarters · filed 2026-07-09 | $468.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $235.00K derived: sum of 2 quarters · filed 2026-06-01 | $347.00K derived: sum of 3 quarters · filed 2026-06-01 | $457.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $228.00K derived: sum of 2 quarters · filed 2025-11-19 | $338.00K 10-Q · filed 2025-11-19 | $434.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $222.00K 10-Q · filed 2025-08-13 | $318.00K derived: sum of 3 quarters · filed 2025-08-13 | $426.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $110.00K 10-Q · filed 2025-05-20 | $206.00K derived: sum of 2 quarters · filed 2025-05-20 | $314.00K derived: sum of 3 quarters · filed 2025-05-20 | $446.00K derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $204.00K derived: sum of 2 quarters · filed 2025-04-01 | $336.00K derived: sum of 3 quarters · filed 2025-04-01 | $421.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $240.00K derived: sum of 2 quarters · filed 2024-11-13 | $325.00K 10-Q · filed 2024-11-13 | $414.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $217.00K 10-Q · filed 2024-08-14 | $306.00K derived: sum of 3 quarters · filed 2024-08-14 | $392.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $85.00K 10-Q · filed 2024-05-10 | $174.00K derived: sum of 2 quarters · filed 2024-05-10 | $260.00K derived: sum of 3 quarters · filed 2024-05-10 | $345.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $175.00K derived: sum of 2 quarters · filed 2024-03-29 | $260.00K derived: sum of 3 quarters · filed 2024-03-29 | $343.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $171.00K derived: sum of 2 quarters · filed 2023-11-13 | $254.00K 10-Q · filed 2023-11-13 | $336.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $168.00K 10-Q · filed 2023-08-11 | $250.00K derived: sum of 3 quarters · filed 2023-08-11 | $330.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $83.00K 10-Q · filed 2023-05-12 | $165.00K derived: sum of 2 quarters · filed 2023-05-12 | $245.00K derived: sum of 3 quarters · filed 2023-05-12 | $327.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $162.00K derived: sum of 2 quarters · filed 2023-03-29 | $244.00K derived: sum of 3 quarters · filed 2023-03-29 | $329.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $162.00K derived: sum of 2 quarters · filed 2022-11-10 | $247.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $167.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $85.00K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $9.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |